MedTrace Logo

Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis

NCT02499315 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2016-05-06

No results posted yet for this study

Summary

The purpose of the study is to find out if AMG 357 is safe and tolerated by women with Rhematoid Arthritis.

Conditions

Interventions

DRUG

AMG 357

Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.

DRUG

Placebo

Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02499315 on ClinicalTrials.gov